Calliditas Therapeutics to Present Data at ERA 2024 May 23 – 26 in Stockholm
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced upcoming data presentations and a sponsored symposium at the 61[st] European Renal Association (ERA) Congress, in Stockholm, Sweden on May 23 – 26, 2024.Data presentations will include an efficacy analysis of Nefecon (TARPEYO® (budesonide) delayed release capsules)) in primary immunoglobulin A nephropathy (IgAN) as well as a real-world analysis of the challenges associated with the use of systemic glucocorticoids (SGC) in IgAN. “We are delighted to participate in ERA and look forward to